Synthetic MR Q4: Plan to reach profitability with no new cash - SEB
6 februari, 09:21
6 februari, 09:21
SyntheticMR reported its full Q4, showing headline figures in line with preliminary figures. Further details show positive sales development in Europe and APAC, while Americas remain sluggish. The company has completed the rights issue, injecting SEK 33m before fees, and says it has a clear plan to reach profitability without further injections.
SEB Research
This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.
6 februari, 09:21
SyntheticMR reported its full Q4, showing headline figures in line with preliminary figures. Further details show positive sales development in Europe and APAC, while Americas remain sluggish. The company has completed the rights issue, injecting SEK 33m before fees, and says it has a clear plan to reach profitability without further injections.
SEB Research
This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.
Rapporter
Analys
Rapporter
Analys
1 DAG %
Senast
OMX Stockholm 30
−0,08%
(13:24)
Ekobrott
Idag, 13:22
Günther Mårder släpps ur häktet
OMX Stockholm 30
1 DAG %
Senast
3 053,44